Navigation Links
SAFC Expands PharmaGrade Raw Materials Portfolio for Biopharmaceutical Manufacturing
Date:11/13/2012

ST. LOUIS, Nov. 13, 2012 /PRNewswire/ -- Sigma-Aldrich® Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), has added more than 25 new raw materials to its portfolio of PharmaGrade products. Launched earlier this year, the PharmaGrade portfolio is comprised of over 65 high-quality buffers, amino acids and specialty chemicals, addressing the need for greater supply chain transparency and enhanced risk management for biopharmaceutical manufacturing. PharmaGrade products come with a fully documented production history that highlights consistent and controlled processes compliant with GMP or SAFC 'Elite' grade documentation guidelines. All products in the portfolio feature formal manufacturer qualification, quality assurance review and release of every lot, change control notification, as well as quality and regulatory support documentation. For more information on the PharmaGrade portfolio and its complete listing of products, visit www.safcglobal.com/pharmagrade.

"We have had a tremendous response to the introduction of PharmaGrade and the positive benefits it delivers to our customers," stated Deborah Slagle, Vice President of Marketing and Research Development at SAFC. "We are able to offer raw materials that encourage quality by design in the early phases of development, while increasing our customers' and potential customers' confidence in the raw materials they are using. More importantly, this line of products saves time for clients that are looking for hard-to-find products with readily available documentation."

The April 2012 acquisition of Research Organics has enabled SAFC to increase its PharmaGrade offering, while complementing the Company's existing raw materials portfolio. The expanded manufacturing capacity made available by Research Organics also enables SAFC to provide customers with dual sourcing of biological buffers. With the addition of dedicated resources and increased capabilities to the PharmaGrade product line, the transition of Research Organics into SAFC has proven beneficial for customers and successful for SAFC.

"Our goal is simple. We want to be recognized as the supplier of choice within the biopharmaceutical and high technology industries we serve," added Gilles Cottier, President of SAFC. "The acquisition of Research Organics supports us in fulfilling this goal in the biopharmaceutical space and allows us to provide our customers with the kind of quality and supply chain transparency they need. We are pleased that our efficiency in integrating Research Organics capabilities with existing SAFC technologies has brought our customers a substantially increased PharmaGrade materials portfolio in a very short period of time."

The foregoing release contains forward-looking statements that can be identified by terminology such as  "tremendous response," "addressing the need," "supports," "allows," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. There can be no guarantee that the SAFC PharmaGrade product offering will continue to meet the demands of the marketplace. Nor can there be any guarantee that any of these products will achieve any particular levels of revenue in the future. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. In particular, management's expectations regarding these products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About SAFC: SAFC, the custom manufacturing and services business unit of Sigma-Aldrich Corporation, is recognized as a top 10 global specialty chemicals and biologics supplier. As a trusted manufacturer for the life science and high technology industries, SAFC works closely with customers to resolve development challenges and accelerate the product pipeline utilizing its global "Centers of Excellence" and dedicated manufacturing facilities. Its rich portfolio includes high-purity inorganic materials for high technology applications, critical raw materials and extensive biologics safety testing services for biopharmaceutical manufacturing, and complex, high-potent APIs and key intermediates for pharmaceutical manufacturing. For more information, visit www.safcglobal.com.

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company whose biochemical, organic chemical products, kits and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology SAFC manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university and government institutions, hospitals and industry. The Company operates in 38 countries and has nearly 9,100 employees whose objective is to provide excellent service worldwide. Sigma-Aldrich is committed to accelerating customer success through innovation and leadership in Life Science and High Technology. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

©2012 Sigma-Aldrich Co. LLC. All rights reserved. SAFC and Sigma-Aldrich are trademarks of Sigma-Aldrich Co. LLC.

 


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
2. BioSurplus Expands, Debuts New 8000 Square Foot Warehouse and Service Facility
3. RxAlly Expands National Network With Addition Of Nineteen Community Pharmacy Organizations Representing Over 2,000 Pharmacies
4. Clinical Interest in BioElectronics Products Expands to the Wound Care Market
5. S1 Biopharma Expands Focus to Include Male Sexual Health
6. PRA Expands Operations in Europe
7. USANA Health Sciences Expands Award-Winning Research and Development Team
8. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
9. Argus Expands Specialty Pharmacy with Amber Pharmacy Collaboration
10. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
11. BHR Pharma Expands SyNAPSe® Trial into Thailand, China and Russia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... TORONTO , Sept. 6, 2017 /PRNewswire/ ... new knowledge and skills while treating their ... for hands-on experience without involving patients. Simulation ... skills. Clinicians can carry out procedures, refine ... at risk. Integration of new technology, such ...
(Date:9/6/2017)... NeuroRx, a clinical stage biopharma company developing the first oral ... granted Fast Track status by the US Food and Drug ... by NRX-101 (D-cycloserine + lurasidone). The company will shortly begin ... targeting patients who are admitted to Emergency Departments with ASIB ... ...
(Date:9/5/2017)... Colo. , Sept. 5, 2017 Sapheneia ... XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party Vendor ... existing CT scanners and allows compliance with current MITA ... Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically designed ... and alerts of potential radiation doses over a predefined ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Collins Concrete ... for clients that rely on safety and cleanliness. This unique flooring system uses ... has been used for centuries for its antimicrobial properties. Unlike antibiotics, which kill ...
(Date:9/20/2017)... Houston, TX (PRWEB) , ... September 20, 2017 ... ... the date of the much-anticipated fall event , Look Awesome This Autumn ... demonstrations, personalized consultations, special pricing and refreshments. , Mirror Mirror Beauty Boutique ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers ... Athletic Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence ... Athletic Trainers are acknowledged by their peers with accolades and highly prestigious awards. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t ... risk of price gouging for their prescription drugs, according to a new comparison ... isn’t negotiating on our behalf, there’s no consistency in drug pricing among drug ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the ... in an average life. This mouse sets out on a journey that will show ... Mouseson” is the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has ...
Breaking Medicine News(10 mins):